Potentiation of erythropoiesis

Patent Number: 5032507

This patent covers the discover that follicle stimulating hormone releasing protein (FRP) can potentiate the activity of erythropoitin in terms of induce erythropoiesis. The patent covers this concept from three perspectives in its three independent claims. The first perspective is "a method for determining the erythrodifferentiation-potentiating capacity of hematopoietic stem cells". The second describes an ex vivo expansion of erythropoietic cells followed by subsequent re-introduction", whereas the third covers a " diagnostic assay kit for testing the capacity of hematopoietic progenitor cells to undergo erythrodifferentiation". All methods involve the use of culturing in EPO and FRP. Given the new evidence that EPO may be involved in stimulating stem cells to perform numerous tasks, including differentiate into neurons, or expand endogenous neural precursors, it may be interesting to see if FRP can potentiate these effects.

View this patent on the USPTO website.